Marqeta Inc vs uniQure N.V. Ordinary Shares — how do they compare? Marqeta Inc trades at $18.1 (market cap $1.93B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Marqeta Inc is the larger of the two by market cap, and Marqeta Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MQ | QURE | |
|---|---|---|
Market Cap | $1.93B | $1.48B |
Volume | 915,027 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $20.32 | $70.59 |
52-Week Low | $15.04 | $9.03 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.25B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.18, down 0.6% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 showing 17% net revenue growth and GAAP profitability. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. Cash flow turned positive in 2025 at $86.42M, a significant improvement from prior years' losses.
Outlook is mixed: strong revenue growth and product initiatives support upside, but high P/E of 206.22 and thin net margin of 1.53% pose valuation risks. Analyst consensus is cautious with a $11.38 price target, well below current levels. Key risks include contract renewals in Q3 2026 and competitive pressures in fintech.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →